Indication
Pseudomonal Lung Infection
1 clinical trial
1 product
Clinical trial
A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects With Cystic Fibrosis and Chronic Pulmonary Pseudomonas Aeruginosa (Pa) InfectionStatus: Completed, Estimated PCD: 2022-12-14
Product
AP-PA02